Encompass Health Corporation (EHC) Income Statement

The quarterly trajectory shows consistent sequential expansion rather than a single step change, which suggests growth is driven by a combination of bed additions and rising discharge volumes rather than acquisitions. Management's commentary on Medicare Advantage mix as a growth driver implies that managed care contracting is becoming a meaningful source of volume, which may improve occupancy but also increases exposure to negotiated rates. Investors should monitor whether growth remains in the low double digits as MA penetration matures, since the growth durability depends on sustained referral flow from acute-care partners.

The gross margin series is not internally consistent across periods, and the 2026Q3 drop coincides with a jump in reported cost of revenue to $1.3 billion, which suggests a reclassification of clinical labor or other costs between COGS and operating lines. Operating margin remained within a narrow 16.5% to 19.0% band across all ten quarters, which points to stable underlying profitability more than the gross line implies. Analysts should normalize gross margin before comparing against peers such as Ensign Group, whose 15.8% gross margin reflects a different reporting structure.

Operating income compounding at a pace broadly in line with revenue implies that EHC is not yet capturing significant incremental operating leverage, as margins remained roughly flat around 17% to 19%. Overhead efficiency appears reasonable given the stable SG&A dollars against a growing top line. Whether margin expansion materializes will depend on whether clinical labor costs, which sit outside SG&A, continue to absorb incremental revenue.